[HTML][HTML] British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)

CS Haworth, J Banks, T Capstick, AJ Fisher, T Gorsuch… - Thorax, 2017 - thorax.bmj.com
Background Since the publication of the British Thoracic Society (BTS) Guideline on the
'Management of opportunistic mycobacterial infections' in 2000, our understanding of the …

Practical guidance for clinical microbiology laboratories: mycobacteria

BA Forbes, GS Hall, MB Miller, SM Novak… - Clinical microbiology …, 2018 - Am Soc Microbiol
Mycobacteria are the causative organisms for diseases such as tuberculosis (TB), leprosy,
Buruli ulcer, and pulmonary nontuberculous mycobacterial disease, to name the most …

Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline

CL Daley, JM Iaccarino, C Lange… - Clinical Infectious …, 2020 - academic.oup.com
Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of
which can produce disease in humans of all ages and can affect both pulmonary and …

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in …

RA Floto, KN Olivier, L Saiman, CL Daley, JL Herrmann… - Thorax, 2016 - thorax.bmj.com
Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can
cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory …

[HTML][HTML] NTM drug discovery: status, gaps and the way forward

ML Wu, DB Aziz, V Dartois, T Dick - Drug discovery today, 2018 - Elsevier
Highlights•Incidence of lung disease caused by non-TB mycobacteria (NTM) is
increasing.•Current treatments are ineffective.•There is an urgent need to establish a drug …

[HTML][HTML] Drug resistance in nontuberculous mycobacteria: mechanisms and models

S Saxena, HP Spaink, G Forn-Cuní - Biology, 2021 - mdpi.com
Simple Summary Recently, there has been a considerable rise in infections caused by
nontuberculous mycobacteria (NTM). These mycobacteria, which comprise a large and …

Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease

RJ Wallace Jr, BA Brown-Elliott, S McNulty, JV Philley… - Chest, 2014 - Elsevier
BACKGROUND There is no large study validating the appropriateness of current treatment
guidelines for Mycobacterium avium complex (MAC) lung disease. This is a retrospective …

Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease

WJ Koh, BH Jeong, SY Kim, K Jeon… - Clinical Infectious …, 2017 - academic.oup.com
Background Treatment outcomes of patients with Mycobacterium abscessus subspecies
abscessus lung disease are poor, and the microbial characteristics associated with …

Nontuberculous mycobacteria—overview

WJ Koh - Microbiology spectrum, 2017 - Am Soc Microbiol
Nontuberculous mycobacteria (NTM) are emerging pathogens that affect both
immunocompromised and immunocompetent patients. The development of molecular …

[HTML][HTML] New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria

MJ Nasiri, M Haeili, M Ghazi, H Goudarzi… - Frontiers in …, 2017 - frontiersin.org
Infectious diseases caused by clinically important Mycobacteria continue to be an important
public health problem worldwide primarily due to emergence of drug resistance crisis. In …